AKBA Q4 2018 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$366M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M-31.5% YoY

Gross Profit

$52M87.2% margin

Operating Income

-$90M-150.6% margin

Net Income

-$88M-147.7% margin

EPS (Diluted)

$-0.76

QoQ Revenue Growth

+12.6%

Cash Flow

Operating Cash Flow

-$74M

Free Cash Flow

-$75M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$997M

Total Liabilities

$361M

Stockholders' Equity

$636M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$87M	-31.5%
Gross Profit	$52M	$19M	+175.5%
Operating Income	-$90M	$11M	-893.0%
Net Income	-$88M	$12M	-819.6%

Revenue Segments

License Collaboration And Other Revenue

$53M100%